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Objectives. Early change in rheumatoid arthritis (RA) is characterised by periarticular osteopenia. We investigated the relationship
of early metacarpal digital X-ray radiogrammetry bone mineral density (DXR-BMD) change rate (RC-BMD, mg/cm2/month)
to longitudinal changes in hand and feet radiographic and wrist MRI scores over 1 year. Materials and Methods. 10 RA patients
completed the study and hadwrist 3T-MRI and hand and feet X-rays at various time points over 1 year.MRIwas scored by RAMRIS,
X-ray was done by van der Heijde modified Sharp scoring, and RC-BMD was analysed using dxr-online. Results. There was good
correlation amongst the two scorers for MRI measures and ICC for erosions: 0.984, BME: 0.943, and synovitis: 0.657. Strong
relationships were observed between RC-BMD at 12-week and 1-year change in wrist marrow oedema (BME) (𝑟 = 0.78, 𝑃 = 0.035)
but not with erosion, synovitis, or radiographic scores. Conclusion. Early RC-BMD correlates with 1-year wrist BME change, which
is a known predictor of future erosion and joint damage. However, in our pilot study, early RC-BMD did not show relationships to
MRI erosion or radiographic changes over 1 year.This may reflect a slower kinetic in the appearance of MRI/radiographic erosions,
generating the hypothesis that RC-BMDmay be a more sensitive and early structural prognostic marker in RA follow-up.
1. Introduction
Radiographic imaging (X-ray) has traditionally been impor-
tant in diagnosis, as per 1987 American College of Rheuma-
tology (ACR) criteria [1] and subsequent evaluation of
patients with rheumatoid arthritis (RA) [2–4]. Evaluation of
the extent and rate of structural damage in routine clinical
practice involves hand and feet radiographs [5, 6] and the
findings may inform treatment change and optimisation.
An early radiographic change in RA is periarticular
osteopenia [7]. Early bone mineral density loss is a predictor
of differentiation to RA in undifferentiated arthritis [8] and
also predicts future joint damage in RA [9]. Plain radiographs
have the limitation that they do not assess synovitis and bone
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Table 1: Demographics of completed study group.
Age
(yrs) BMI
Weight
(Kg)
RA duration
(months)
ESR
(mm/hr)
CRP
(mg/L) TJC/28 SJC/28
Patient global
VAS (mm) DAS28
Mean 53.8 25.9 68.8 68.56 25.3 6.5 5.2 5.7 19.6 3.93
St. dev. 10.6 4.2 10.8 51.5 28.7 3.2 4.0 3.9 12.3 1.3
Range 38–70 19.8–31.8 53–85 5–128 5–100 <2–12 0–12 1–13 1–32 1.54–5.57
BMI: bodymass index; ESR: erythrocyte sedimentation rate (mm/hour); CRP: C reactive protein (mg/L); TJC/28: 28 joint count; SJC/28: 28 swollen joint count;
DAS 28: disease activity score based on 28 joints.
marrow oedema (BME) [10]. It is known that BME is an early
disease activity measure that predicts future erosions [11].
The time and costs involved in having repeated MRI as a
follow-up imaging modality limits its potential. Radiographs
are a cheaper, more readily available, quicker, and routinely
performed investigation in clinical practice for RA follow-up.
Various X-ray scoring methods have been described to assess
joint damage in RA in the context of clinical trials [3].
Rosholm et al. described a new automated radiogram-
metricmethod to assess bonemineral density loss from single
hand radiographs [12]. This technique has been used in early
RA [9, 13, 14]. To date, few studies have compared thismethod
with MRI disease activity change over time [15–17]. In this
study, we evaluated the relationship between automated
early metacarpal bone mineral density loss, disease activity
using high field strength 3T wrist MRI, and hand and feet
radiographic scores over a year in patients with established
RA undergoing standard clinical care.
2. Material and Methods
2.1. Patients. The study was approved by local research ethics
committee (reference: 06/Q0401/97) and informed written
consents were obtained according to the Declaration of
Helsinki guidelines.Thirteen rheumatoid arthritis patients, as
per 1987 ACR criteria, were enrolled. Ten patients completed
study (1 patient withdrew due to claustrophobia, 1 dropped
out after baseline and another after week 12). Table 1 shows
completed study group demographics. 1 patient did not
attend week 12 visit.
Inclusion criteria included subjects aged ≥18 years, diag-
nosed with RA as per revised 1987 ACR criteria and had
evidence of current or recent active disease with poor prog-
nostic markers for joint damage, as evidenced by rheumatoid
factor or anticyclic citrullinated protein antibodies (anti-
CCP) positive or at least two radiographic erosions. They
were also required to have a swollen joint/s in the hand to be
MRI scanned. Exclusion criteria included history of drug or
alcohol abuse, MRI contraindications, estimated glomerular
filtration rate (eGFR) <60mL/min, contrast allergy, preg-
nancy/nursing, blood donation, Steinbrocker function score
stage IV, subject unable to position in the scanner, recent hand
joint injection, current or recent biological antirheumatic
treatment, or any other subject deemed unsuitable by the
investigator.
Patients had 5 study visits: day 1, week 4, week 12, week
24, and week 52. At all visits, various clinical assessments
were performed, which amongst others included erythrocyte
sedimentation rate (ESR), C-reactive protein (CRP), 28-joint
disease activity score (DAS28), joint assessments, and MRI
safety check including blood test, pregnancy test, and 3T
wrist MRI. Hand and feet radiographs were performed at
all visits except week 4. Drug history with respect to disease
modifying drugs (DMARDS) as part of their standard clinical
carewas documented and includedmethotrexate (𝑛 = 9), sul-
fasalazine (𝑛 = 3), hydroxychloroquine (𝑛 = 3), prednisolone
(𝑛 = 3), and interim depomedrone intramuscular injection
for flare up (𝑛 = 2).
2.2. Imaging Protocols. 3T wrist MRI (Philips Achieva) was
performed using a dedicated SENSE wrist coil in a purpose
built subject “bridge” positioning device [18, 19] to allow for
similar and comfortable wrist positioning in a longitudinal
fashion.
Imaging parameters used were (1) T2w TSE: TR/TE/FA:
9000ms/55ms/90∘, FOV: 120 × 97 × 82mm3, acquisition
matrix: 208 × 168, slices: 140 (thickness: −0.58mm, order:
interleaved), reconstructed voxel: 0.54 × 0.54 × 1.16mm,
Time: 7min 48.2 sec; (2) pre- and postcontrast T1wFFE:
TR/TE/FA: 11ms/2.3ms/20∘, FOV: 120 × 98 × 82mm3,
acquisition matrix: 240 × 196, slices: 164 (scan mode: 3D),
reconstructed voxel: 0.5 × 0.5 × 0.5mm, and time: 5min
55.4 sec; (3) dynamic contrast enhanced (DCE): TR/TE/FA:
3.8ms/2.1ms/20∘, FOV: 120 × 95 × 80mm3, acquisition
matrix: 96 × 75, slices: 127 (scan mode: 3D, Technique:
T1FFE), reconstructed voxel: 1.25 × 1.25 × 0.63mm, dynamic
time: 10.3 sec, and time: 6min 52.8 sec. There was a 40 sec
delay from the start of image acquisition to contrast injec-
tion (Gadolinium-DTPA (Gd) (0.2mL/kg)). A total of 5080
images were acquired (127 slices with 40 frames); (4) T1wFFE
proset: TR/TE/FA: 11ms/3.5ms/20∘, FOV: 120× 98× 82mm3,
acquisition matrix: 240 × 196, slices: 164 (scan mode: 3D),
reconstructedmatrix: 0.5× 0.5× 0.5, and time: 5min 55.4 sec.
2.3. Imaging Analysis. Registered and aligned anonymized
wrist MRI scans (𝑛 = 52) were scored using OMERACT
RAMRIS [20]. This scoring method scores the wrist joint,
using an atlas, for synovitis (0–3) at three points in the joint
(maximum score of 9), erosions (0–10) for each bone (max-
imum score 150), and marrow oedema (0–3) for each bone
(maximum score 45). Scoring was done by two experienced
(more than 5 years) radiologists (Keshthra Satchithananda
and Adrian K. P. Lim). Radiologists were blinded and scored
the MRI scans independently in a random order without
knowing either the time point or disease status of the subjects,
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Table 2: Mean and Std. Dev. for MRI disease activity RAMRIS scores over 1 year. The mean total radiographic score change is also shown.
Baseline Week 4 Week 12 Week 24 Week 52
Synovitis (0–9) 5.8 ± 1.9 5.8 ± 2.7 5.3 ± 2.9 5.2 ± 1.8 5.1 ± 1.7
Erosions∗ (0–150) 10.7 ± 13.9 11.1 ± 17.2 14.5 ± 16.9 11.7 ± 15.1 13.1 ± 16.8
BME (0–45) 7.4 ± 9.5 6.9 ± 8.7 7.1 ± 8.5 5.8 ± 7.6 7.8 ± 8.0
Total X-ray score (max 448) 33.6 — 34.4 34.7 35.4
∗Erosions score excluded a patient with complete fused carpal joints.
Figure 1: It shows region of interest (ROI) placed on (2–4)th
metacarpals. Cortical thickness and bone width are calculated for
each point with multiple such measurements made over the ROI,
allowing for DXR-BMD to be calculated.
and mean scores were calculated. X-rays in chronological
order (𝑛 = 43) were scored jointly on PACS using van der
Heijde modified Sharp (vdH Sharp) scoring, evaluating both
hands and feet for erosion and joint space narrowing [3].
Digital X-ray radiogrammetry (DXR-online, SECTRA,
Sweden) was used to calculate DXR-BMD [12]. Using auto-
mated algorithms, the computer identifies second to fourth
metacarpal diaphysis on digital hand radiographs and places
regions of interest (ROI) for a length of 2 cm, 1.8 cm, and
1.6 cm for 2nd, 3rd, and 4thmetacarpal, respectively. Cortical
thickness and bone width are calculated for each point and
multiple such measurements made over the ROI (Figure 1).
The final DXR-BMD is calculated based on the formula [12]
DXR-BMD = 𝑐 ∗ VPAmc ∗ (1 − 𝑃), where 𝑐 is a constant, 𝑃
is an estimated porosity, and VPA is the weighted average of
bone volume per projected area. The rate of change in DXR-
BMD (RC-BMD) (mg/cm2/month) was assessed. 9 patients’
radiographs were analysed over the year and 8 patients’ data
were available at 12 weeks. 1 subject did not have MRI BME
assessment at week 52; hence, only 7 pairs of datasets with
week 12 RC-BMD and week 52 MRI were available.
2.4. Statistical Analysis. A repeated measure analysis of vari-
ance (ANOVA) was performed to evaluate radiographic and
Table 3: Interreader correlation for RAMRIS scoring.
MRI disease
activity
Interclass
correlation
coefficient (ICC)
95% confidence interval 𝑛
Synovitis 0.657 0.46 0.78 51
Erosions 0.984 0.97 0.99 51
BME 0.943 0.9 0.96 50
MRI scores over time. Normality was tested using Shapiro-
Wilk test. Minimal detectable change at 1 year, MDC
95
(95%
confidence), was calculated. For normally distributed data,
Pearson correlation was used; otherwise, spearman correla-
tion was used, to evaluate statistical correlation between rate
of change in bone mineral density (RC-BMD) and various
MRI andX-ray scores. Interclass correlation coefficient (ICC)
was used to assess total RAMRIS scores between two readers.
A two-way mixed model with consistency type was used.
SPSS software was used for analysis. 𝑃 values <0.05 (2 tailed)
were considered statistically significant.
3. Results
ThewristMRI disease activity scores of this cohort of patients
on standard routine treatment over the year remained stable;
mean changes (% of maximum score) in synovitis, erosion,
and BME scores were−0.7 (−7.7%), 2.4 (1.6%), and 0.4 (0.8%),
respectively, at 1 year (Table 2). These were not significant.
The minimal detectable change, MDC
95
(95% confidence),
at 1 year for MRI synovitis, erosion∗, and BME were 3.56,
16.51, 5.97, respectively, with standard error of measurement
for synovitis: 1.28, erosion∗: 5.95, and BME: 2.15 (∗1 subject
with fused bones was excluded).
There was good correlation amongst the two independent
blinded scorers for MRI measures and interclass correlation
coefficient (ICC) single measures for erosions: 0.984, BME:
0.943, and synovitis: 0.657 (Table 3).
Total hand and feet X-ray scores showed a small increase
from baseline score of 33.6 to end of year score of 35.4 (out
of a maximum score of 448), thereby an increase of 0.4%.
This was not significant.TheMDC
95
for total X-ray score was
4.56 and standard error of measurement was 1.64. 4 out of 10
RA patients showed no change in score at 1 year. 2 patients
progressed with hand erosions and increase in score of 1 and
3, respectively. 1 patient had progression in hand and feet by
8 score points, more weighted in the feet (6 score points),
which had erosion and joint space narrowing but only slight
increase in joint space narrowing in hand with an increase in
4 Arthritis
Table 4: DXR-BMD average and rate change (RC-BMD) over time.
RC-BMD over 12 weeks
[mg/cm2/month]
Average BMD change over 12
weeks [g/cm2]
RC-BMD over 1 year
[mg/cm2/month]
Average BMD change over 1
year [g/cm2]
Average −0.48 −0.0008 −0.55 −0.006
Std. Dev. 1.5 0.004 1.2 0.01
1 2 3 4 5 6 7 8
0
2
4
12-week wrist BME change 
12-week RC-BMD 
−6
−4
−2
Figure 2: 12-week RC-BMD change mapped with 12-week wrist
BME change for 8 rheumatoid patients over a year. Majority of
patients with lowRC-BMDhad increased BME change andmajority
of patients with increase in RC-BMD had reduced BME.
score by 2. 3 patients progressed in feet alone. No significant
differences were seen in radiographic scores over time.
RC-BMD(mg/cm2/month)was similar over 12weeks and
1 year, −0.48 ± 1.5 and −0.55 ± 1.2, respectively (Table 4).
12-week RC-BMD showed no significant correlation with
any 12-week and 24-week change scores. 12-week RC-BMD
correlated with BME change (𝑟 = 0.78, 𝑃 = 0.035) and ESR
change (𝜌 = 0.91, 𝑃 = 0.001) at 1 year. No correlation was
seen with the change in DAS28, MRI erosion, synovitis, or
X-ray scores.
Figure 2 shows 12-week RC-BMD and 12-week BME
change plotted for each patient. Figure 3 shows line graph for
all patients with MRI and X-ray scores over time.
4. Discussion
Plain radiographs form a routine and widely used way of
assessing RA joint damage in clinical practice [4, 5]. Applica-
tion of newer imaging modalities, such as MRI, plays a more
crucial role in identifying early changes, like early erosions,
synovitis, and BME, that lead to radiographic damage and
morbidity on the long term. There has been an increasing
trend towards using these in clinical trials with comparison
made to changes on radiographs [21–23].
The early changes on radiographs, that is, bone mineral
density loss, are quite commonly seen in RA. Loss of
metacarpal bone mineral density is known to predict RA
development in recent onset arthritis [8]. It is also described
as an independent predictor of future damage in RA patients
and potentially an important tool in daily clinical work [24].
Inflammatory cytokines such as TNF and IL6 have been
linked with increased osteoclast activity, which have been
associated with alteration of bone metabolism in early RA
[25, 26]. Therapies inhibiting inflammatory cytokines have
shown to reduce bone loss in RA [27]. Bonemarrow edema in
RA indicates the presence of active inflammation and osteitis,
which is also associated with inflammatory cytokines [28].
These have shown improvement with anti-TNF treatment
[29].
In the present study, we saw strong association between
these two measures. There were significant correlations
between early (12 weeks) RC-BMD and 1-year change in wrist
BME. This could indicate that DXR-BMD change possibly
mirrors osteitis seen on MRI macroscopically to already
known microscopic and cytokine associations.
Stewart et al. revealed that 1-year change in DXR-BMD
in RA patients predicts who will become erosive at 4 years
[30]. In early phase clinical trials, early imaging predictive
biomarkers are required, and thus DXR-BMD offers poten-
tial. In the present study, we evaluated even earlier DXR-
BMD change, that is, over 3 months. This correlated with
BME at 1 year, which is known to predict future radiographic
joint damage in RA [11]. Also of note was that the RC-
BMD change over 12 weeks and 1 year was observed to
be similar, though with increased loss at 1 year (Table 4).
Hence, this early measure could enable clinicians to use a
readily available low cost modality to follow up patients. In
recent studies, 3-month hand bone loss and baseline MRI
findings were reported to predict 1-year MRI erosion in early
RA [15] and large 3-month DXR bone loss was seen in
patients with MRI erosion progression [17]. We did not see
any significant correlation in our cohort between 3-month
RC-BMD and 1-year MRI erosion/radiographic scores.There
could be several reasons for this; firstly, our patients were
mostly the ones with established RA on standard combina-
tion disease modifying therapy. Most studies have looked
at early RA or undifferentiated arthritis and these cohorts
were often selected for poor prognostic factors and thus
exhibited a much faster average rate of structural damage.
Secondly, in patients with established RA on standard clinical
care, these findings could reflect a slower kinetic in the
appearance of MRI/radiographic erosions than that of RC-
BMD change reflecting more rapid periarticular bone loss
and thus generating the hypothesis that RC-BMD may be a
sensitive and early structural prognosticmarker inRA follow-
up. A major limitation of our study was the small number of
patients followed up.
In our small cohort, we observed slight increases in 3
patients (RC-BMD, Figure 2). On further evaluation, it was
found that these subjects had a long duration of RA. One
patient had fused carpal bones and may have had secondary
sclerosis, a finding that could also limit our results. In another
subject (disease duration: 5months), we saw rapid loss in RC-
BMD −3.2mg/cm2/month and high BME score throughout
the year (day 1, week 4, week 12, week 24, and week 52, with
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Figure 3: Line graph of MRI synovitis, erosion, BME, and radiographic scores over time for each patient.
RAMRIS scores: 28, 26, 27, 22.5, and 23 out of 45), Figure 4.
Hence, in spite of a small decrease in BME at 1 year, the bone
loss continued as the overall burden of osteitis remained large.
In future studies, this should be taken into consideration and
patients with high osteitis scores included.
It is well known that oral steroids reduce bone mineral
density. In our pilot study, of the 8 patients with RC-BMD
results at week 12, only 2 patients were on regular oral
prednisolone, out of which 1 subject showed increase in RC-
BMD. Hence, the results observed in the cohort as a whole
for change in RC-BMD over time could not be accounted by
the use of steroid therapy.
We used 3T wrist MRI in our study. It is known that at
higher field strengths there is better signal to noise ration and
hence better resolution [31–34]. This is crucial when imaging
small joints, including wrists, which are commonly involved
in RA. We also saw good ICC between two independent
scorers for the MRI scans.
We noted that stable patients on routine clinical care
still have very minimal increase (% of maximum score) in
MRI erosion (1.6%) and BME (0.8%) and X-ray radiographic
(0.4%) scores. The small increase in X-ray scores was largely
due to the progression in feet. Only in 2 out of 10 subjects
hand erosion score increased by 1 and 3 score points. This is
very small change and would be within the realms of stable
disease on visual inspection or measurement error. A reason
for the overall stable MRI measures could be mixed cohort
of patients in our pilot study, some with early and others
with long standing disease with established joint damage. It
is possible that the disease kinetics may have a different rate
of progression in these subgroups, though this hypothesis
will need to be tested in other studies. But even with this
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Figure 4: Image shows wrist MRI disease activity at (a) day 1, (b) week 4, (c) week 12, (d) week 24, and (e) week 52 in patient with early
disease (disease duration 5 months at baseline). Over the year, there is large amount of BME (RAMRIS scores: 28, 26, 27, 22.5, and 23 at day
1, week 4, week 12, week 24, and week 52). The patient also had rapid loss in RC-BMD at week 12. There is also marked synovitis in the wrist
joint with transient improvement at week 4 distal to triquetrum (red circle).
small amount of change, we saw correlations between early
RC-BMD and 1-year wrist BME, thus offering a promising
potential as an early follow-up imaging tool in routine clinical
management of RA patients.
Though there are some considerations to be taken into
account with DXR analysis, this method requires two images
to be acquired 3months apart andwith the same type of X-ray
modality. The system automatically rejects change calcula-
tions when the samemodality type is not used. If all the same
types of X-ray modalities were upgraded simultaneously,
BMD change during the upgrade period will not be available.
The cost of BMD measurements with DXR analysis varies
with licensing costs and number of examinations performed,
but it is typically, including the cost of the X-ray, less than the
cost of MRI.
A limitation of the current pilot study is the small cohort
size. These pilot findings generate hypothesis for future
studies that will need to be tested in larger, defined patient
groups and different MRI imaging platforms. Nevertheless,
this is, to our knowledge, the only study to evaluate RC-BMD
using DXR and 3T wrist MRI in a longitudinal fashion in
established RA patients with wide range of disease duration.
5. Conclusions
In conclusion, we have seen in our pilot study that early
12-week RC-BMD change correlates with 1-year wrist BME
change. BME is well known to be a predictor of future
erosions. However, in this cohort, we did not detect any
correlations between early RC-BMD and the progression of
radiologic damage in the form of erosions at 1 year. This
raises the possibility that in patients with established RA
on standardised treatment and a low annualized rate of
radiographic progression, DXR may offer a tool as an early
indicator of insidious damage progression over the longer
termandpossibly also of functional loss.Our findings and the
generated hypothesis need to be further evaluated in a larger
cohort of patients.
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